Angion shares drop 56% as kidney transplant drug misses endpoint in late-stage trial

seekingalpha2021-10-27

ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from Angion Biomedica(NASDAQ:ANGN)and Vifor Pharma,did not meet its primary endpoint in a phase 3 trial. ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Vin309
2021-10-27
Vin309
Wt
chefbean
2021-10-27
chefbean
Hee

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1137943402?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-27 16:51","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1137943402","market":"us","top_or_hot":-1,"title":"Angion shares drop 56% as kidney transplant drug misses endpoint in late-stage trial","media":"seekingalpha","content":"<div>\n<p>ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from Angion Biomedica(NASDAQ:ANGN)and Vifor Pharma,did not meet its primary endpoint in a phase 3 trial.\n...</p>\n\n<a href=\"https://seekingalpha.com/news/3758498-angion-shares-drop-55-as-kidney-transplant-drug-misses-endpoint-in-late-stage-trial\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Angion shares drop 56% as kidney transplant drug misses endpoint in late-stage trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAngion shares drop 56% as kidney transplant drug misses endpoint in late-stage trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-27 16:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3758498-angion-shares-drop-55-as-kidney-transplant-drug-misses-endpoint-in-late-stage-trial><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from Angion Biomedica(NASDAQ:ANGN)and Vifor Pharma,did not meet its primary endpoint in a phase 3 trial.\n...</p>\n\n<a href=\"https://seekingalpha.com/news/3758498-angion-shares-drop-55-as-kidney-transplant-drug-misses-endpoint-in-late-stage-trial\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://seekingalpha.com/news/3758498-angion-shares-drop-55-as-kidney-transplant-drug-misses-endpoint-in-late-stage-trial","article_id":"1137943402","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137943402","pubTimestamp":1635324699,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from A","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"由于肾移植药物在晚期试验中错过终点，Angion股价下跌56%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANGN":0.9},"content_text":"ANG-3777, a drug for kidney transplant patients at risk for developing delayed graft function from Angion Biomedica(NASDAQ:ANGN)and Vifor Pharma,did not meet its primary endpoint in a phase 3 trial.\nThe difference in estimated glomerular filtration rate (eGFR) between the candidate and placebo was not statistically significant.\nAn analysis of only those who completed the trial showed that that those in the ANG-3777 arm had a 12-month eGFR of 57.1mL/min/1.73m2 versus 52.2mL/min/1.73m2 for placebo. The company said this is \"potentially indicative of biologic activity.\"\nAngion said it had $100M in cash as of Sept. 30.\nIn June, Angionabandoned pursuing ANG-3777 as a COVID-19 therapy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":855965111,"gmtCreate":1635325774305,"gmtModify":1635325792583,"author":{"id":"3555908735229300","authorId":"3555908735229300","name":"Vin309","avatar":"https://static.tigerbbs.com/9ca4de1ca05f1d625f1bcdbc1d790726","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3555908735229300","authorIdStr":"3555908735229300"},"htmlText":"Wt","listText":"Wt","text":"Wt","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855965111","repostId":1137943402,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":855982746,"gmtCreate":1635324859616,"gmtModify":1635324859616,"author":{"id":"3554935180693279","authorId":"3554935180693279","name":"chefbean","avatar":"https://static.tigerbbs.com/75bcdd1d22221ef3b8f10c64b73ea420","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3554935180693279","authorIdStr":"3554935180693279"},"htmlText":"Hee","listText":"Hee","text":"Hee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855982746","repostId":1137943402,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":22,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137943402"}